Supplementary Data from Targeting Podoplanin for the Treatment of Osteosarcoma
Ai Takemoto(Japanese Foundation For Cancer Research), Naoya Fujita(Japanese Foundation For Cancer Research), Ryohei Katayama(Japanese Foundation For Cancer Research), Asami Kobayashi(Chemotherapy Foundation), Mamoru Kakino(Gifu Pharmaceutical University), Yuki Funauchi(Japan Association for Development of Community Medicine), Marie Lebel(Chemotherapy Foundation), Kengo Takeuchi(Japanese Foundation For Cancer Research), Kazue Tsuji‐Takayama(Statens Serum Institut), Seiichi Matsumoto(Fukuda Denshi (Japan)), Kenji Ichihara(API (Japan)), Satoshi Takagi(Japanese Foundation For Cancer Research), Takao Ukaji(Juntendo University), Miho Takami(Chemotherapy Foundation), Yoshiya Sugiura(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Tetsuo Noda, Minoru Sugawara, Tokuichi Kawaguchi(The Cancer Institute Hospital), Nobuhiko Gyobu(API (Japan))
Cited by 0
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
|Nature Communications|2017|409
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264